Financial Performance - Net profit attributable to shareholders was ¥325,675,134.56, representing a decrease of 20.85% year-on-year[18] - Operating revenue for the first nine months was ¥2,650,423,323.06, down 11.55% from the same period last year[18] - Basic earnings per share decreased to ¥0.72, down 20.88% from ¥0.91 in the same period last year[21] - The weighted average return on net assets was 6.87%, a decrease of 2.57 percentage points compared to the previous year[21] - The company reported non-operating income of ¥1,030,948.99 for the current period, compared to ¥17,208,324.19 for the same period last year[24] - Total operating revenue for Q3 2020 was ¥992,242,109.74, a decrease of 4.6% compared to ¥1,040,229,243.60 in Q3 2019[50] - Net profit for Q3 2020 was ¥145,948,224.21, compared to ¥158,547,330.90 in Q3 2019, representing a decline of 7.5%[57] - Total profit for Q3 2020 was ¥165,559,667.47, a decrease of 13.9% from ¥192,758,613.16 in Q3 2019[57] - The company’s total comprehensive income for Q3 2020 was ¥93.94 million, compared to ¥100.80 million in Q3 2019[66] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,031,340,332.37, an increase of 8.99% compared to the previous year-end[18] - The company's total assets reached RMB 6,031,340,332.37, up from RMB 5,533,753,104.69, marking an increase of 9.00%[39] - Total liabilities increased to ¥1,439,695,548.12, up from ¥947,975,661.52, representing a growth of approximately 51.9% year-over-year[47] - The total current liabilities surged to ¥1,392,661,072.69, up from ¥906,276,952.47, which is an increase of around 53.7%[47] - The company's total liabilities increased significantly, with accounts payable at RMB 336,895,462.00, down from RMB 360,598,640.47, indicating a decrease of 6.58%[39] Cash Flow - The net cash flow from operating activities for the first nine months was ¥312,188,929.85, a decline of 13.04% compared to the previous year[18] - The net cash flow from operating activities was CNY 171,643,459.51, a decrease of 38.3% compared to CNY 278,033,992.32 in the same period last year[72] - The total cash inflow from investment activities was CNY 230,420,786.38, significantly higher than CNY 68,482,241.46 in the previous year[71] - The net cash flow from financing activities was CNY 13,865,098.48, compared to a negative cash flow of CNY -118,778,486.00 in the same period last year[71] - The cash inflow from sales of goods and services was CNY 1,984,387,295.24, down from CNY 2,227,324,440.98 year-over-year[72] Shareholder Information - The total number of shareholders at the end of the reporting period was 31,700[25] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 165,673,200 shares, accounting for 36.54% of the total[25] Inventory and Expenses - The company's inventory increased to RMB 618,980,721.72, compared to RMB 600,897,945.05, reflecting a growth of 3.59%[39] - The company's financial expenses decreased by 503.08%, resulting in a loss of RMB 4,234,247.03, compared to a gain of RMB 1,050,480.81 in the previous period[31] - Research and development expenses increased to ¥58,010,002.34 in Q3 2020, up 23.5% from ¥46,805,053.85 in Q3 2019[54] - Sales expenses for Q3 2020 were ¥317,051,667.05, slightly up from ¥310,498,943.01 in Q3 2019, showing an increase of 2.5%[54] Future Outlook - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[64]
辰欣药业(603367) - 2020 Q3 - 季度财报